文献速递儿科与产科急症心脑血管急症重症综合管理与镇静镇痛

氯胺酮用于神经指征危重患儿气管插管:多中心回顾性分析

Ketamine Use in the Intubation of Critically Ill Children with Neurological Indications: A Multicenter Retrospective Analysis.
PubMed 文献 · Neurocrit Care · 2023-05-09
一句话结论多中心回顾性分析显示,神经指征危重患儿插管时使用氯胺酮与围插管复合不良结局无显著关联(校正OR 1.34,95%CI 0.99-1.81,p=0.057)。

该研究为多中心回顾性观察性队列研究,纳入53个国际儿科重症监护病房和急诊科2014至2020年因原发神经指征行气管插管的危重患儿(<18岁),数据来自NEAR4KIDS登记数据库。21,562次插管中2,073次(9.6%)为原发神经指征,其中190次为创伤性脑损伤/创伤;495次(23.9%)使用了氯胺酮,使用率从2014年10%升至2020年41%(p<0.001)。复合不良结局(低氧血症<80%、低血压/高血压、心脏骤停、心律失常)见于289次(13.9%),氯胺酮组更常见(17.0% vs 13.0%,p=0.026);校正混杂因素后氯胺酮与复合不良结局无显著关联(校正OR 1.34,95%CI 0.99-1.81,p=0.057),仅神经创伤插管时亦无关联(10.6% vs 7.7%,p=0.528)。结论认为该回顾性队列未证明神经指征插管时围操作期使用氯胺酮与围插管低氧血症和血流动力学不稳定风险增加相关。

要点

  • 53个国际PICU和急诊科2014-2020年数据:21,562次插管中2,073次(9.6%)为原发神经指征,190次为创伤性脑损伤/创伤。
  • 神经指征插管中氯胺酮使用率从2014年10%升至2020年41%(p<0.001),总使用率23.9%(495/2,073)。
  • 复合不良结局总体13.9%(289次),氯胺酮组17.0% vs 非氯胺酮组13.0%(p=0.026);校正后OR 1.34(95%CI 0.99-1.81,p=0.057),未达统计学显著。
  • 仅神经创伤插管亚组:氯胺酮组10.6% vs 非氯胺酮组7.7%(p=0.528),无显著关联。
  • 氯胺酮使用与呼吸衰竭共指征、困难气道史、使用迷走神经阻滞剂、呼吸暂停氧合和视频喉镜相关。

适用人群与场景

  • 53个国际儿科重症监护病房和急诊科中,2014至2020年因原发神经指征行气管插管的危重患儿(<18岁)。
  • 纳入标准:年龄<18岁且因原发神经指征行气管插管;数据来自NEAR4KIDS多中心登记数据库。

研究设计与关键结果

  • 研究类型:多中心回顾性观察性队列研究,53个国际儿科重症监护病房和急诊科,数据来自NEAR4KIDS登记数据库2014至2020年。
  • 样本量:21,562次气管插管中2,073次(9.6%)为原发神经指征,包括190次创伤性脑损伤/创伤。
  • 氯胺酮使用:495次(23.9%),从2014年10%升至2020年41%(p<0.001)。
  • 复合不良结局(低氧血症<80%、低血压/高血压、心脏骤停、心律失常):289次(13.9%),氯胺酮组17.0% vs 非氯胺酮组13.0%(p=0.026)。
  • 校正地点、年龄、合并诊断、呼吸衰竭和休克、困难气道史、操作者特征、插管设备、呼吸暂停氧合、迷走神经阻滞剂和神经肌肉阻滞后,氯胺酮与复合不良结局无显著关联(校正OR 1.34,95%CI 0.99-1.81,p=0.057)。
  • 仅神经创伤插管亚组:氯胺酮组10.6% vs 非氯胺酮组7.7%(p=0.528)。
  • 氯胺酮使用与呼吸衰竭共指征、困难气道史、使用迷走神经阻滞剂、呼吸暂停氧合和视频喉镜相关。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该回顾性队列未证明神经指征插管时围操作期使用氯胺酮与围插管低氧血症和血流动力学不稳定风险增加相关。
  • 氯胺酮使用率从2014年10%升至2020年41%(p<0.001),提示临床实践中对神经指征患儿使用氯胺酮增多。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ketamine has traditionally been avoided for tracheal intubations (TIs) in patients with acute neurological conditions. We evaluate its current usage pattern in these patients and any associated adverse events.

METHODS: We conducted a retrospective observational cohort study of critically ill children undergoing TI for neurological indications in 53 international pediatric intensive care units and emergency departments. We screened all intubations from 2014 to 2020 entered into the multicenter National Emergency Airway Registry for Children (NEAR4KIDS) registry database. Patients were included if they were under the age of 18 years and underwent TI for a primary neurological indication. Usage patterns and reported periprocedural composite adverse outcomes (hypoxemia < 80%, hypotension/hypertension, cardiac arrest, and dysrhythmia) were noted.

RESULTS: Of 21,562 TIs, 2,073 (9.6%) were performed for a primary neurological indication, including 190 for traumatic brain injury/trauma. Patients received ketamine in 495 TIs (23.9%), which increased from 10% in 2014 to 41% in 2020 (p < 0.001). Ketamine use was associated with a coindication of respiratory failure, difficult airway history, and use of vagolytic agents, apneic oxygenation, and video laryngoscopy. Composite adverse outcomes were reported in 289 (13.9%) Tis and were more common in the ketamine group (17.0% vs. 13.0%, p = 0.026). After adjusting for location, patient age and codiagnoses, the presence of respiratory failure and shock, difficult airway history, provider demographics, intubating device, and the use of apneic oxygenation, vagolytic agents, and neuromuscular blockade, ketamine use was not significantly associated with increased composite adverse outcomes (adjusted odds ratio 1.34, 95% confidence interval CI 0.99-1.81, p = 0.057). This paucity of association remained even when only neurotrauma intubations were considered (10.6% vs. 7.7%, p = 0.528).

CONCLUSIONS: This retrospective cohort study did not demonstrate an association between procedural ketamine use and increased risk of peri-intubation hypoxemia and hemodynamic instability in patients intubated for neurological indications.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Loi MV, Lee JH, Huh JW, et al. Ketamine Use in the Intubation of Critically Ill Children with Neurological Indications: A Multicenter Retrospective Analysis. Neurocrit Care. 2023. PMID: 37160847. doi:10.1007/s12028-023-01734-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。